West Pharmaceutical shares are up about 20% since CNBC flagged the valuation in August, and the latest earnings give it reasons to expect further gains.
Recap by typeshit. Full story at CNBC.
Obesity specialist Dr. Alexandra Sowa says long-term use makes cost the flashpoint, as insurers and employers scale back coverage and Medicare benefits face a 2027 question.
With 30% of covering employers weighing cuts, Wegovy and Zepbound users should check their plans now. Includes current self-pay prices and tips for appeals.
Endpoints News
Endpoints News reports Lilly's direct-to-patient sales model, built on Americans paying hundreds a month, is now becoming part of its plans overseas.
GEN ranks the best-selling drugs by 2025 sales, and Lilly's weight loss shot outpaced names like Merck's Keytruda on growth.
Mounjaro brought in $10.7 billion and Zepbound $5.4 billion. Lilly says about seven in 10 Medicare Bridge patients use its drugs, while Foundayo hit $184 million.
The telehealth company says it serves nearly 3 million people and is sticking with 2030 targets of at least $6.5 billion in revenue.
Loading…